Half-year report · HY
4671.TEDINET S100WYRV
Period2025-04-01 → 2025-09-30
Filed2025-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥43.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥21.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥803m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥803m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥36.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥36.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥36.2bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥25.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥25.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥73m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥860m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥79.87 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥181.81 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.46 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥79.66 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.81 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.25 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.3% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.4% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥266m |
| Clinical Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥13.4bn |
| Clinical Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥13.4bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Clinical Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥936m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥241m |
| ICT Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥681m |
| ICT Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥681m |
| ICT Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥166m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥21.6bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥21.6bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥176m |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥726m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥347m |
| ICT Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥538m |
| ICT Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥538m |
| ICT Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Allowance for doubtful accounts ca | Prior1YearInstant | -0 | JPY |
| Allowance for doubtful accounts ca | InterimInstant | -0 | JPY |
| Current assets | Prior1YearInstant | 18228000000 | JPY |
| Current assets | InterimInstant | 17790000000 | JPY |
| Buildings and structures | Prior1YearInstant | 9397000000 | JPY |
| Buildings and structures | InterimInstant | 9425000000 | JPY |
| Accumulated depreciation buildings and structures | Prior1YearInstant | -5157000000 | JPY |
| Accumulated depreciation buildings and structures | InterimInstant | -5298000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 4239000000 | JPY |
| Buildings and structures net | InterimInstant | 4127000000 | JPY |
| Land | Prior1YearInstant | 5382000000 | JPY |
| Land | InterimInstant | 5386000000 | JPY |
| Lease assets ppe | Prior1YearInstant | 1327000000 | JPY |
| Lease assets ppe | InterimInstant | 1327000000 | JPY |
| Accumulated depreciation lease assets ppe | Prior1YearInstant | -1208000000 | JPY |
| Accumulated depreciation lease assets ppe | InterimInstant | -1232000000 | JPY |
| Lease assets net ppe | Prior1YearInstant | 119000000 | JPY |
| Lease assets net ppe | InterimInstant | 95000000 | JPY |
| Other ppe | Prior1YearInstant | 5289000000 | JPY |
| Other ppe | InterimInstant | 5832000000 | JPY |
| Accumulated depreciation other ppe | Prior1YearInstant | -3763000000 | JPY |
| Accumulated depreciation other ppe | InterimInstant | -3904000000 | JPY |
| Other net ppe | Prior1YearInstant | 1525000000 | JPY |
| Other net ppe | InterimInstant | 1928000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 11267000000 | JPY |
| Property plant and equipment | InterimInstant | 11537000000 | JPY |
| Other ia | Prior1YearInstant | 543000000 | JPY |
| Other ia | InterimInstant | 564000000 | JPY |
| Intangible assets | Prior1YearInstant | 543000000 | JPY |
| Intangible assets | InterimInstant | 564000000 | JPY |
| Investment securities | Prior1YearInstant | 3675000000 | JPY |
| Investment securities | InterimInstant | 4071000000 | JPY |
| Other ioa | Prior1YearInstant | 2308000000 | JPY |
| Other ioa | InterimInstant | 2392000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -4000000 | JPY |
| Allowance for doubtful accounts ioa by group | InterimInstant | -4000000 | JPY |
| Investments and other assets | Prior1YearInstant | 5979000000 | JPY |
| Investments and other assets | InterimInstant | 6459000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 17790000000 | JPY |
| Noncurrent assets | InterimInstant | 18561000000 | JPY |
| Assets | Prior1YearInstant | 36019000000 | JPY |
| Assets | InterimInstant | 36352000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 4284000000 | JPY |
| Notes and accounts payable trade | InterimInstant | 4413000000 | JPY |
| Short term loans payable | Prior1YearInstant | 400000000 | JPY |
| Short term loans payable | InterimInstant | 400000000 | JPY |
| Income taxes payable | Prior1YearInstant | 525000000 | JPY |
| Income taxes payable | InterimInstant | 510000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 482000000 | JPY |
| Provision for bonuses | InterimInstant | 503000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |